JP2007505164A5 - - Google Patents

Download PDF

Info

Publication number
JP2007505164A5
JP2007505164A5 JP2006533682A JP2006533682A JP2007505164A5 JP 2007505164 A5 JP2007505164 A5 JP 2007505164A5 JP 2006533682 A JP2006533682 A JP 2006533682A JP 2006533682 A JP2006533682 A JP 2006533682A JP 2007505164 A5 JP2007505164 A5 JP 2007505164A5
Authority
JP
Japan
Prior art keywords
trifluoroethyl
amino
nitro
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505164A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/018456 external-priority patent/WO2004110978A2/en
Publication of JP2007505164A publication Critical patent/JP2007505164A/ja
Publication of JP2007505164A5 publication Critical patent/JP2007505164A5/ja
Pending legal-status Critical Current

Links

JP2006533682A 2003-06-10 2004-06-09 アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての１−アミノナフタレン類 Pending JP2007505164A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47725603P 2003-06-10 2003-06-10
PCT/US2004/018456 WO2004110978A2 (en) 2003-06-10 2004-06-09 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors

Publications (2)

Publication Number Publication Date
JP2007505164A JP2007505164A (ja) 2007-03-08
JP2007505164A5 true JP2007505164A5 (enExample) 2007-07-26

Family

ID=33551695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533682A Pending JP2007505164A (ja) 2003-06-10 2004-06-09 アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての１−アミノナフタレン類

Country Status (4)

Country Link
US (1) US20060142387A1 (enExample)
EP (1) EP1636167A2 (enExample)
JP (1) JP2007505164A (enExample)
WO (1) WO2004110978A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1851204A1 (en) * 2005-02-23 2007-11-07 SmithKline Beecham Corporation Naphthalene derivatives as modulators of the glucocorticoid receptor
WO2006113552A2 (en) * 2005-04-15 2006-10-26 Smithkline Beecham Corporation Cyanoarylamines
WO2008021796A2 (en) * 2006-08-09 2008-02-21 Smithkline Beecham Corporation Pyrrolidinone anilines as progesterone receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
BRPI0908719A2 (pt) * 2008-03-31 2015-08-18 Univ Columbia Metodos de diagnóstico, prevenção e tratamento de doenças de massa óssea
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
US20130053448A1 (en) 2010-05-12 2013-02-28 Louis O'Dea Therapeutic Regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
MY176727A (en) * 2012-12-03 2020-08-20 Pfizer Selective androgen receptor modulators
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
US9920043B2 (en) 2014-05-15 2018-03-20 Pfizer Inc. Crystalline form of 6-[(4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]iosoquinoline-1-carbonitrile
BR112016027778A2 (pt) * 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
AU2016250562B2 (en) * 2015-04-21 2020-08-13 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3286164B1 (en) 2015-04-21 2024-05-29 Oncternal Therapeutics, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
CN113750091B (zh) 2015-04-29 2025-03-11 雷迪厄斯制药公司 用于治疗癌症的方法
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
MX389702B (es) 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
US10385008B2 (en) 2017-01-05 2019-08-20 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCL
WO2019222272A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
KR102792490B1 (ko) 2018-07-04 2025-04-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
WO2020051344A1 (en) 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
CN113348163B (zh) 2019-02-12 2024-10-08 雷迪厄斯制药公司 方法和化合物
WO2020232119A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4313991A1 (en) 2021-03-23 2024-02-07 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
IL308104A (en) 2021-05-03 2023-12-01 Nuvation Bio Inc Nuclear hormone receptor-targeted compounds against cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2670376A (en) * 1951-10-16 1954-02-23 Nepera Chemical Co Inc N-alpha-naphthyl n, n' n,'-trialkylethylene diamines
US3139421A (en) * 1960-03-14 1964-06-30 Parke Davis & Co Azo compounds and methods for producing same
US3291808A (en) * 1961-08-14 1966-12-13 Parke Davis & Co Naphthalene diamine compounds and methods for their production
US3218309A (en) * 1961-08-14 1965-11-16 Parke Davis & Co Azo compounds
GB1086988A (en) * 1965-04-05 1967-10-11 Gevaert Photo Prod Nv Hydrazine compounds
SU465792A3 (ru) * 1968-11-06 1975-03-30 Хиноин Гиогисцер-Ес Вегиесцети Термекек Гиара Рт (Фирма) Способ получени гетероциклических соединений
US4209302A (en) * 1979-05-10 1980-06-24 Morton-Norwich Products, Inc. Marker for petroleum fuels
JPS6058227B2 (ja) * 1981-03-06 1985-12-19 株式会社島津製作所 ナフトイルニトリル誘導体、その製法および発螢光試薬
FR2547828B1 (fr) * 1983-06-23 1985-11-22 Centre Nat Rech Scient Materiau luminescent comportant une matrice solide a l'interieur de laquelle est reparti un compose fluorescent, son procede de preparation et son utilisation dans une photopile
JPS6341833A (ja) * 1986-08-07 1988-02-23 Toray Ind Inc 有機非線形光学化合物
JPH06184152A (ja) * 1991-11-18 1994-07-05 Sanwa Kagaku Kenkyusho Co Ltd 新規な化合物、その製法及び該化合物を主成分とする脳機能改善剤
JP2983141B2 (ja) * 1993-10-06 1999-11-29 株式会社三和化学研究所 新規化合物及び該化合物を有効成分とする脳機能改善剤
BR9916999A (pt) * 1999-01-14 2001-10-30 Bayer Ag Heterociclos de 2-arilimino substituìdos ecomposições contendo-os, para uso como agentesde ligação do receptor de progesterona
EP1319007B9 (en) * 2000-09-19 2007-10-10 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2003011824A1 (en) * 2001-07-31 2003-02-13 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2005085185A1 (en) * 2004-03-03 2005-09-15 Smithkline Beecham Corporation Aniline derivatives as selective androgen receptor modulators
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
AU2005247405A1 (en) * 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
US20070004679A1 (en) * 2004-05-17 2007-01-04 Nathalie Schlienger Androgen receptor modulators and methods of treating disease using the same

Similar Documents

Publication Publication Date Title
JP2007505164A5 (enExample)
JP2007509852A5 (enExample)
JP2011527334A5 (enExample)
JP2008507532A5 (enExample)
JP2007509103A5 (enExample)
JP2005526723A5 (enExample)
JP2007505922A5 (enExample)
JP2004507465A5 (enExample)
JP2005523920A5 (enExample)
JP2009507909A5 (enExample)
JP2010526145A5 (enExample)
JP2008540554A5 (enExample)
JP2004511466A5 (enExample)
CA2614529A1 (en) Pyridazinone derivatives as thyroid hormone receptor agonists
JP2010514832A5 (enExample)
JP2005507932A5 (enExample)
JP2007502804A5 (enExample)
NZ587547A (en) Modulators of ATP-Binding Cassette Transporters
JP2004520292A5 (enExample)
RU2005137403A (ru) Новые замещенные 3-сера-индолы
GB0402653D0 (en) Compounds
JP2010501584A5 (enExample)
JP2006507220A5 (enExample)
JP2007500245A5 (enExample)
JP2010536821A5 (enExample)